Clinical Trials
343 trials[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Aalborg University Hospital
PAPAYA
Royal Marsden NHS Foundation Trust
BASICS
Washington University School of Medicine
HED
Medical University of Vienna
PANEL
University Hospital, Rouen
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Peking Union Medical College Hospital
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
PeriPharm
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
TILsOV
Centre Oscar Lambret
ACCRAPAN
Centre Oscar Lambret
GEMCOL
Centre Oscar Lambret
ANOXICOL
Centre Oscar Lambret
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
University of Iowa
FAB
Leiden University Medical Center
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
M.D. Anderson Cancer Center
ENDOCOL
University Hospital, Lille
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors
Washington University School of Medicine
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
PAIR HPV
Institut Curie
COCHISE
Institut Bergonié
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
CAN-STAMP
University Health Network, Toronto
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
Effect of a Childcare Resource on Cervical Cancer Prevention
University of Texas Southwestern Medical Center
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
National Cheng-Kung University Hospital
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
M.D. Anderson Cancer Center
AM-003
University of Virginia
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Exercise Preconditioning in Ovarian Cancer
University of Virginia
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
NIRAPK
Hospices Civils de Lyon
IMMUVIX
Institut du Cancer de Montpellier - Val d'Aurelle
KYSTOV
University Hospital, Montpellier
SCC-BAREDU
University of Oklahoma
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Mayo Clinic
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
HPVAC2
University Hospital, Brest
Pembrolizumab and Olaparib in Cervical Cancer Patients
Baptist Health South Florida